Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group (Q42996746)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2000

Language	Label	Description	Also known as
English	Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group	scientific article published in January 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Thierry Poynard

1

object named as

T Poynard

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

J McHutchison

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Z Goodman

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

M H Ling

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Albrecht

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

211-218

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310131

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.510310131

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42996746&oldid=1976296917"